215 related articles for article (PubMed ID: 8036608)
21. Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity.
Robak E; Sysa-Jedrzejewska A; Dziankowska B; Torzecka D; Chojnowski K; Robak T
Arch Immunol Ther Exp (Warsz); 1998; 46(6):375-80. PubMed ID: 9883317
[TBL] [Abstract][Full Text] [Related]
22. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
Higgs BW; Zhu W; Richman L; Fiorentino DF; Greenberg SA; Jallal B; Yao Y
Int J Rheum Dis; 2012 Feb; 15(1):25-35. PubMed ID: 22324944
[TBL] [Abstract][Full Text] [Related]
23. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion.
Straub RH; Pongratz G; Schölmerich J; Kees F; Schaible TF; Antoni C; Kalden JR; Lorenz HM
Arthritis Rheum; 2003 Jun; 48(6):1504-12. PubMed ID: 12794817
[TBL] [Abstract][Full Text] [Related]
24. [Proinflammatory cytokines in inactive lupus erythematosus patients].
Lesiak A; Sysa-Jedrzejowska A; Narbutt J; Lukamowicz J; Robak E; Wozniacka A
Przegl Lek; 2005; 62(9):838-42. PubMed ID: 16541713
[TBL] [Abstract][Full Text] [Related]
25. Raised serum APRIL levels in patients with systemic lupus erythematosus.
Koyama T; Tsukamoto H; Miyagi Y; Himeji D; Otsuka J; Miyagawa H; Harada M; Horiuchi T
Ann Rheum Dis; 2005 Jul; 64(7):1065-7. PubMed ID: 15576416
[TBL] [Abstract][Full Text] [Related]
26. Markers of inflammation and atherosclerosis in Egyptian patients with systemic lupus erythematosus.
Sabry AA; Elbasyouni SR; Kalil AM; Abdel-Rahim M; Mohsen T; Sleem A
Nephrology (Carlton); 2006 Aug; 11(4):329-35. PubMed ID: 16889573
[TBL] [Abstract][Full Text] [Related]
27. Tumor necrosis factor induced adhesion molecule serum concentrations in Henoch-Schönlein purpura and pediatric systemic lupus erythematosus.
Gattorno M; Vignola S; Barbano G; Sormani MP; Sabatini F; Buoncompagni A; Picco P; Pistoia V
J Rheumatol; 2000 Sep; 27(9):2251-5. PubMed ID: 10990243
[TBL] [Abstract][Full Text] [Related]
28. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC; Chung SJ; Park YB; Lee SK
Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
[TBL] [Abstract][Full Text] [Related]
29. [Tumor necrosis factor-alpha and kidney damage in rheumatoid arthritis].
Tsybul'ko SV; Baranov AA; Borodin AG; Korshunov NI; Kirdianov SIu
Ter Arkh; 2001; 73(5):8-11. PubMed ID: 11517757
[TBL] [Abstract][Full Text] [Related]
30. Cortisol catabolism by lymphocytes of patients with systemic lupus erythematosus and rheumatoid arthritis.
Klein A; Buskila D; Gladman D; Bruser B; Malkin A
J Rheumatol; 1990 Jan; 17(1):30-3. PubMed ID: 2313669
[TBL] [Abstract][Full Text] [Related]
31. A novel mutation (T61I) in the gene encoding tumour necrosis factor receptor superfamily 1A (TNFRSF1A) in a Japanese patient with tumour necrosis factor receptor-associated periodic syndrome (TRAPS) associated with systemic lupus erythematosus.
Ida H; Kawasaki E; Miyashita T; Tanaka F; Kamachi M; Izumi Y; Huang M; Tamai M; Origuchi T; Kawakami A; Migita K; Motomura M; Yoshimura T; Eguchi K
Rheumatology (Oxford); 2004 Oct; 43(10):1292-9. PubMed ID: 15280569
[TBL] [Abstract][Full Text] [Related]
32. A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety, and clinical effects.
Gao IK; Scholz P; Boehme MW; Norden C; Lemmel EM
Rheumatol Int; 2002 Jun; 22(2):45-51. PubMed ID: 12070674
[TBL] [Abstract][Full Text] [Related]
33. [Serum level of beta-glucuronidase as potential indicator of disease activity in rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE)].
Falkenbach A; Unkelbach U; Gottschalk R; Kaltwasser JP
Med Klin (Munich); 1991 Sep; 86(9):465-8. PubMed ID: 1943985
[TBL] [Abstract][Full Text] [Related]
34. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
[TBL] [Abstract][Full Text] [Related]
35. Serum concentrations of cardiac troponin-I in patients with rheumatoid arthritis, systemic lupus erythematosus, primary Sjogren's syndrome and Graves' disease.
Al-Awadhi AM; Olusi S; Hasan EA; Abdullah A
Singapore Med J; 2007 Sep; 48(9):847-9. PubMed ID: 17728967
[TBL] [Abstract][Full Text] [Related]
36. Levamisole can modulate the serum tumor necrosis factor-alpha level in patients with recurrent aphthous ulcerations.
Sun A; Wang JT; Chia JS; Chiang CP
J Oral Pathol Med; 2006 Feb; 35(2):111-6. PubMed ID: 16430742
[TBL] [Abstract][Full Text] [Related]
37. Serum cytokines in different histological variants of rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Latosiewicz R; Cylwik B; Skowronski J; Chwiecko J
J Rheumatol; 2001 Jun; 28(6):1211-7. PubMed ID: 11409111
[TBL] [Abstract][Full Text] [Related]
38. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H
Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
[TBL] [Abstract][Full Text] [Related]
39. [Clinical value of soluble tumor necrosis factor-alpha receptors in patients with systemic lupus erythematosus].
Krichevskaia OA; Kliukvina NG; Aleksandrova EN; Samsonov MIu; Nasonov EL
Klin Med (Mosk); 2004; 82(10):51-5. PubMed ID: 15584602
[TBL] [Abstract][Full Text] [Related]
40. Anti-TNF-alpha-induced systemic lupus syndrome.
Debandt M; Vittecoq O; Descamps V; Le Loët X; Meyer O
Clin Rheumatol; 2003 Feb; 22(1):56-61. PubMed ID: 12605321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
